Source study found

Story checked

Iberdomide Combo Boosts Complete Response in Myeloma (opens in a new tab)

medscape.com · 2026-10-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Iberdomide Combo Boosts Complete Response in Myeloma

medscape.com · 2026-10-06

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

3 supported
2 not covered

Open claim evidence

The source study

Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial

The Lancet. Oncology · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe benefit was seen across prespecified subgroups, including patients with lenalidomide-exposed or lenalidomide-refractory disease.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile supports an overall MRD-negative complete response advantage, but it does not provide subgroup results for prespecified subgroups or for lenalidomide-exposed/lenalidomide-refractory patients. The claim may be true in the full paper, but it is not verifiable from the supplied abstract-depth profile.

Study evidence

In the prespecified primary MRD ITT cohort (first 420 patients with ≥12 months follow-up), iberdomide + daratumumab + dexamethasone produced higher MRD-negative complete response rates than daratumumab + bortezomib + dexamethasone.41% (85/207) vs 21% (44/213); stratified proportion difference 20.1% (95% CI 11.5–28.6), p<0.0001; odds ratio 2.8 (95% CI 1.8–4.3).

“an open-label, randomised, controlled, phase 3 trial”

Claim 2 of 5Not coveredSustained MRD-negative complete response lasting at least 6 months and overall response rate were also higher with the iberdomide regimen.View evidenceHide evidence

As statedSustained MRD-negative complete response: 16% vs 8%; overall response rate difference 12.5%

Why this verdict

The supplied profile reports the primary MRD-negative complete response endpoint but does not include abstract-level evidence for sustained MRD-negative complete response lasting at least 6 months or for overall response rate. The causal framing could be appropriate for a randomized trial if those outcomes were reported, but the supplied abstract-depth profile is insufficient to verify the claim or its stated magnitudes.

Study evidence

“an open-label, randomised, controlled, phase 3 trial”

Claim 3 of 5SupportedIn a phase 3 trial of relapsed or refractory multiple myeloma, iberdomide plus daratumumab and dexamethasone significantly improved minimal residual disease (MRD)-negative complete response rates compared with daratumumab, bortezomib, and dexamethasone.View evidenceHide evidence

As stated41% vs 21%; stratified proportion difference 20.1%; OR 2.8; P < .0001

Why this verdict

Supported by the abstract-level profile: the EXCALIBER-RRMM phase 3 randomized trial reported higher MRD-negative complete response with iberdomide+daratumumab+dexamethasone versus daratumumab+bortezomib+dexamethasone, with the stated values matching the profile (41% vs 21%; stratified difference 20.1%; OR 2.8; p<0.0001). Because this was a randomized interventional comparison, the story’s causal framing of the regimen improving this endpoint is acceptable at this depth.

Study evidence

“an open-label, randomised, controlled, phase 3 trial”

Claim 4 of 5SupportedThe iberdomide regimen was linked to more grade 3 or 4 adverse events, especially neutropenia and infection, and more serious adverse events than the comparator regimen.View evidenceHide evidence

As statedGrade 3/4 adverse events 92% vs 70%; neutropenia 84% vs 11%; infection 39% vs 22%; serious adverse events 58% vs 41%

Why this verdict

Supported by the safety unit. The profile reports higher grade 3–4 adverse events with the iberdomide regimen (92% vs 70%), higher neutropenia (84% vs 11%), higher infections (39% vs 22%), and higher serious adverse events (58% vs 41%). The story uses associational language ('linked to'), which fits the safety reporting.

Study evidence

Grade 3 or 4 adverse events occurred in 187/204 (92%) of patients receiving iberdomide + daratumumab + dexamethasone versus 143/204 (70%) receiving daratumumab + bortezomib + dexamethasone.92% vs 70% (absolute difference 22 percentage points)

“Safety was assessed in all participants who received at least one dose of study treatment.”

Claim 5 of 5SupportedThe trial’s co-primary endpoints were MRD-negative complete response and progression-free survival, but this report presented the MRD-negative complete response findings while progression-free survival was still being assessed.View evidenceHide evidence

Why this verdict

Supported. The profile states that the dual primary endpoints were MRD-negative complete response and progression-free survival, and that the paper reported the primary analysis of MRD-negative complete response while progression-free survival was not mature/was still being assessed.

Study evidence

“an open-label, randomised, controlled, phase 3 trial”

Study evidence

Screening and randomisation: 1,163 patients screened; 939 randomized (279 in stage 1; 660 in stage 2).

“1163 patients were screened for eligibility of whom 939 patients were randomised, 279 in stage 1 and 660 in stage 2.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The primary MRD analysis was based on the first prespecified 420 randomized patients with at least 12 months follow-up, rather than the full randomized trial population.
The story mentions median follow-up and PFS immaturity, but it does not clearly state that the reported MRD analysis was limited to the first 420-patient prespecified cohort, an important scope limitation for interpreting the results.
From Open-label, multicentre randomized phase 3 trial (EXCALIBER-RRMM); Two-stage open-label randomized phase 3 trial (dose-e
The trial was open-label, which may affect assessment or reporting of some outcomes.
Open-label design is a stated limitation in the profile but is not included in the story claims or caveats.
From Open-label, multicentre randomized phase 3 trial (EXCALIBER-RRMM); Two-stage open-label randomized phase 3 trial (dose-e

6 things the story did carry across

Primary efficacy finding: iberdomide+daratumumab+dexamethasone produced higher MRD-negative complete response than daratumumab+bortezomib+dexamethasone in the prespecified primary MRD analysis cohort.
Safety finding: the iberdomide regimen had higher grade 3–4 adverse events, neutropenia, infections, and serious adverse events; treatment-related deaths were infrequent and numerically similar.
Progression-free survival was a co-primary endpoint but was not mature/reported in this primary MRD-negative complete response analysis.
MRD testing was restricted to patients with suspected complete response or better, so not all randomized patients were systematically assessed for MRD.
Median follow-up was 15.7 months, limiting assessment of durability and longer-term outcomes.
Trial eligibility excluded anti-CD38-refractory and bortezomib-refractory disease; stage 2 allowed only limited prior anti-CD38 exposure, affecting generalisability.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCompare efficacy of iberdomide+daratumumab+dexamethasone versus daratumumab+bortezomib+dexamethasone in relapsed/refractory multiple myeloma, focusing on the primary analysis of MRD-negative complete response (dual primary endpoint).Open-label, multicentre randomized phase 3 trial (EXCALIBER-RRMM)Expand

In plain English

Primary analysis of the EXCALIBER-RRMM phase 3 randomized trial (first 420 ITT patients with ≥12 months follow-up) showed a higher rate of MRD-negative complete response at any time with iberdomide + daratumumab + dexamethasone versus daratumumab + bortezomib + dexamethasone (41% vs 21%; stratified proportion difference 20.1% [95% CI 11.5–28.6], p<0.0001; odds ratio 2.8 [95% CI 1.8–4.3]).

Key findings

In the prespecified primary MRD ITT cohort (first 420 patients with ≥12 months follow-up), iberdomide + daratumumab + dexamethasone produced higher MRD-negative complete response rates than daratumumab + bortezomib + dexamethasone.41% (85/207) vs 21% (44/213); stratified proportion difference 20.1% (95% CI 11.5–28.6), p<0.0001; odds ratio 2.8 (95% CI 1.8–4.3).

“an open-label, randomised, controlled, phase 3 trial”

What this piece can’t prove

Open-label design may influence assessment or reporting of some outcomes.
MRD assessment was restricted to patients with suspected complete response or better; not all randomized patients were systematically assessed for MRD.
Primary MRD analysis is based on the first prespecified 420 patients (early cohort); progression-free survival, the co-primary endpoint in the full confirmatory population, is not yet mature.
Trial excluded patients with anti-CD38-refractory or bortezomib-refractory disease in both stages; stage 2 allowed up to 10% with prior anti-CD38 exposure—this affects generalisability to refractory subgroups.

2human in vivoCharacterize comparative safety/tolerability of the regimens (grade 3–4 AEs, serious AEs, treatment-related deaths).Safety population analysis from a multicentre randomized phase 3 trialExpand

In plain English

In the safety population (all participants who received ≥1 dose), iberdomide + daratumumab + dexamethasone was associated with higher proportions of grade 3–4 adverse events, specific haematological toxicity (neutropenia), infections, and serious adverse events than daratumumab + bortezomib + dexamethasone in the primary MRD analysis cohort. At a median follow-up of 15.7 months, grade 3–4 adverse events occurred in 187/204 (92%) versus 143/204 (70%); neutropenia in 172/204 (84%) versus 23/204 (11%); infections in 80/204 (39%) versus 44/204 (22%); serious adverse events in 119/204 (58%) versus 83/204 (41%), with pneumonia the most common SAE (36/204 [18%] vs 13/204 [6%]); and treatment-related deaths were 3 (1%) versus 2 (1%) (investigator‑assessed).

Key findings

Grade 3 or 4 adverse events occurred in 187/204 (92%) of patients receiving iberdomide + daratumumab + dexamethasone versus 143/204 (70%) receiving daratumumab + bortezomib + dexamethasone.92% vs 70% (absolute difference 22 percentage points)
Neutropenia (reported as a specific adverse event) occurred in 172/204 (84%) with the iberdomide regimen versus 23/204 (11%) with the comparator.84% vs 11% (absolute difference 73 percentage points)

“Safety was assessed in all participants who received at least one dose of study treatment.”

What this piece can’t prove

Investigator attribution of treatment-related deaths may be subjective; adjudication details are not included.

3 further details could not be confirmed from the summary.

3human in vivoDescribe trial conduct and population (screening, randomisation stages, baseline characteristics; contextualizes generalisability).Two-stage open-label randomized phase 3 trial (dose-evaluation then confirmatory dosing)Expand

In plain English

EXCALIBER-RRMM is a two-stage, open-label, randomized, controlled phase 3 trial conducted at 211 hospital and community sites in 31 countries. Of 1,163 screened, 939 were randomized (279 in stage 1; 660 in stage 2). Stage 1 used 1:1:1:1 randomisation across dose-level arms for iberdomide+daratumumab+dexamethasone versus daratumumab+bortezomib+dexamethasone; stage 2 used 1:1 randomisation with a confirmatory iberdomide dose of 1.0 mg. The primary MRD analysis ITT population comprised the first 420 patients (207 assigned to iberdomide+daratumumab+dexamethasone; 213 to daratumumab+bortezomib+dexamethasone). Eligible adults had relapsed or refractory multiple myeloma after one to two prior lines of therapy, ECOG 0–2, and prior ≥partial response followed by progression; anti-CD38-refractory and bortezomib-refractory patients were excluded (stage 2 permitted up to 10% with prior anti-CD38 exposure). Baseline characteristics for the 420-patient MRD ITT cohort: 244 (58%) male, 176 (42%) female; median age 68 years (IQR 60–73); 257 (61%) White. MRD was assessed in patients with suspected complete response or better. The primary MRD analysis was performed once the first 420 patients had at least 12 months' follow-up or had discontinued early.

Key findings

Screening and randomisation: 1,163 patients screened; 939 randomized (279 in stage 1; 660 in stage 2).
Two-stage randomisation schema: stage 1 used 1:1:1:1 allocation for multiple iberdomide dose levels with daratumumab+dexamethasone versus daratumumab+bortezomib+dexamethasone; stage 2 used 1:1 allocation with confirmatory iberdomide dose 1.0 mg. Overall, 800 patients were randomized to the 1.0 mg iberdomide dose cohort or comparator across stages.

“1163 patients were screened for eligibility of whom 939 patients were randomised, 279 in stage 1 and 660 in stage 2.”

What this piece can’t prove

Open-label design (stated in abstract) — lack of blinding may affect assessment/reporting of some outcomes.
Eligibility exclusions: anti-CD38-refractory and bortezomib-refractory patients were excluded, which limits applicability to those refractory subgroups.
Stage 2 allowed up to 10% of patients with prior anti-CD38 exposure, introducing potential heterogeneity between stages.
MRD was assessed only in patients with suspected complete response or better, which constrains MRD ascertainment to a subset of participants rather than whole-cohort screening.
Primary MRD analysis was performed on the first 420 randomized patients after ≥12 months follow-up; results therefore reflect this initial cohort rather than the full planned confirmatory population.

Finally, the search trail

Method layer